CRISPR-mediated TGFBR2 knockout renders human ovarian cancer tumor-infiltrating lymphocytes resistant to TGF-β signaling.
Samantha M FixMarie-Andrée ForgetDonastas Sakellariou-ThompsonYunfei WangTamara M GriffithsMinjung LeeCara L HaymakerAna Lucía DominguezRafet BasarChristopher ReyesSanjay KumarLarissa A MeyerPatrick HwuChantale BernatchezAmir A JazaeriPublished in: Journal for immunotherapy of cancer (2022)
knockout, yielding an expanded OvCa TIL product that was resistant to the immunosuppressive effects of TGF-β. This study lays the groundwork for clinical translation of CRISPR-modified TIL, providing opportunities for engineering more potent TIL therapies not only for OvCa treatment, but for the treatment of other solid cancers as well.